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Summary
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by a loss of immunologic tolerance
to a multitude of self-antigens. Epidemiological data sug-
gest an important role for genes in the etiology of lupus,
and previous genetic studies have implicated the HLA
locus, complement genes, and low-affinity IgG (Fcg) re-
ceptors in SLE pathogenesis. In an effort to identify new
susceptibility loci for SLE, we recently reported the re-
sults of a genomewide microsatellite marker screen in
105 SLE sib-pair families. By using nonparametricmeth-
ods, evidence for linkage was found in four inter-
vals: 6p11-21 (near the HLA), 16q13, 14q21-23, and
20p12.3 (LOD scores 2.0), and weaker evidence in
another nine regions. We now report the results of a
second complete genome screen in a new cohort of 82
SLE sib-pair families. In the cohort 2 screen, the four
best intervals were 7p22 (LOD score 2.87), 7q21 (LOD
score 2.40), 10p13 (LOD score 2.24), and 7q36 (LOD
score 2.15). Eight additional intervals were identified
with LOD scores in the range 1.00–1.67. A combined
analysis of MN cohorts 1 and 2 (187 sib-pair families)
showed that markers in 6p11-p21 (D6S426, LOD score
4.19) and 16q13 (D16S415, LOD score 3.85) met the
criteria for significant linkage. Three intervals (2p15,
7q36, and 1q42) had LOD scores in the range
1.92–2.06, and another 13 intervals had LOD scores in
the range of 1.00–1.78 in the combined sample. These
data, together with other available gene mapping results
in SLE, are beginning to allow a prioritization of ge-
nomic intervals for gene discovery efforts in human SLE.
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Introduction
Systemic lupus erythematosus (SLE [MIM 152700]) is
an autoimmune inflammatory disease that can affect di-
verse organ systems, including the skin, joints, brain,
lungs, and kidneys. The disease is characterized by im-
mune dysregulation, leading to high-level autoantibody
production, immune complex deposition, and vasculitis
(Rothfield 1985). SLE most commonly presents in
women (F:M ratio 9:1) in their childbearing years, and
the overall estimated prevalence in the United States is
∼40 cases/100,000 individuals (Hochberg 1997a).
Epidemiologic studies suggest a strong genetic com-
ponent for susceptibility to SLE. Twin studies show an
overall 10-fold greater risk for disease concordance in
MZ, compared with DZ, twins (Block et al. 1975; Dea-
pen et al. 1992), and familial aggregation studies indicate
a sibling risk ratio (lS [Risch 1990]) of at least 10 (Vyse
and Todd 1996). The genetic hypothesis in SLE is also
supported by the high incidence of SLE in patients with
certain complement deficiencies (C1q, C2, and C4) and
associations of disease and autoantibody production
with HLA class II alleles (Arnett 1997). Polymorphisms
in low-affinity IgG (Fcg) receptors, which are important
for the clearance of immune complexes, are also impli-
cated in the pathogenesis of lupus (Salmon et al. 1996;
Wu et al. 1997).
As one approach to understanding the genetic basis
for susceptibility to SLE, a number of groups have ini-
tiated genomewide marker screens in human SLE (Gaff-
ney et al. 1998; Moser et al. 1998; Shai et al. 1999).
Our group at Minnesota has focused on collecting SLE
sib-pair families (Kearns et al. 1998), and we recently
reported the results of a 341-marker screen in 105 fam-
ilies (MN cohort 1 [Gaffney et al. 1998]). By using non-
parametric multipoint methods, we identified 25 mark-
ers with LOD scores 11.0. Sixteen of these markers
clustered into four distinct intervals: 6p11-p21 (near the
HLA region), 16q13, 14q21-q23, and 20p12. These in-
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tervals had LOD scores 12.00, and nine additional chro-
mosomal regions were identified with LOD scores11.00.
Because it appears likely that SLE, like many complex
genetic diseases, exhibits significant genetic heteroge-
neity, we have continued to identify additional families
suitable for mapping. Herein, we report the results of a
genomewide marker screen in 82 new SLE sib-pair fam-
ilies (MN cohort 2). Overall, the data from this screen
support the evidence for linkage in several of the pre-
viously reported potential susceptibility intervals. In ad-
dition, several new intervals that showed only weak ev-
idence for linkage in the cohort 1 screen were identified
in the present study. A combined analysis ofMN cohorts
1 and 2, together with supportive data from other pub-
lished screens in SLE, allow us now to focus our atten-
tion on discrete genomic intervals that are likely to har-
bor human SLE susceptibility genes.
Families and Methods
SLE Families
The collection of affected sib-pair families for this
study has been described in detail elsewhere (Kearns et
al. 1998). Families were recruited from all regions of the
United States and Canada, and all patients met the 1997
revised criteria for the diagnosis of SLE (Tan et al. 1982;
Hochberg 1997b). After informed consent was obtained
from the patients, verification of the SLE diagnosis was
performed by a review of the patients’ medical records
and an interview with the patients’ physicians. All avail-
able parents were recruited (5 affected) to facilitate the
analysis of identity-by-descent (IBD) allele sharing. If
parents were not available, an unaffected sibling was
recruited to assist in the reconstruction of parental gen-
otypes. Since our recent report (Gaffney et al. 1998), we
have obtained additional information for three of the
cohort 1 pedigrees. The affected sisters in one family
were determined to be half-sibs on the basis of statistics
generated by using the RELATIVE computer algorithm
(Goring and Ott 1997). In a second family, a probable
patient with SLE who had been collected and genotyped
was verified as definitely having SLE, whereas a previ-
ously verified sib with SLE in the same family was de-
termined not to meet the criteria. Finally, 2 parental
samples from cohort 1 were collected and analyzed in
the cohort 2 screen. This additional information altered
the calculated LOD scores slightly in the current analysis
of cohort 1, compared with the previously reported val-
ues (Gaffney et al. 1998). All family relationships in both
cohorts 1 and 2 were confirmed by use of RELATIVE
(Goring and Ott 1997). This study was approved by the
human subjects review board of the University of
Minnesota.
Samples and Genotyping
Genomic DNA was isolated from peripheral blood
mononuclear cells by use of standard methods, and ge-
notyping of families was done essentially as described
elsewhere (Gaffney et al. 1998). For cohort 2, an Applied
Biosystems, Inc. (ABI) fluorescently labeled human link-
age mapping set (v2.0) was used and optimized for mul-
tiplexing markers of similar color into one or two re-
action cocktails. PCR (32 cycles) was done on an ABI
877 Catalyst robotic workstation (5-ml reactions: 5 ng
of genomic DNA, 2.5 mMMgCl2, 0.2 mM dNTPs [Phar-
macia], 0.2 U Amplitaq Gold DNA polymerase [PE Bios-
ystems] in 1# PCR Buffer II [PE Biosystems]). Individual
primer-pair concentrations were in the range of
0.31–3.30 pmol/reaction, on the basis of the results of
optimization runs.
Pooled amplification products were electrophoresed
through 5% polyacrylamide gels (FMC Bioproducts) for
2 h at 3000 V on an ABI 377 DNA Sequencer. Semi-
automated fragment sizing was done by use of GENE-
SCAN software (v2.1; ABI), followed by allele calling
with GENOTYPER software (v2.0; ABI). Each genotype
was reviewed manually by 2 members of the research
team to confirm the accuracy of allele calling. Poorly
performing markers (a total of 34 markers randomly
distributed across the genome) were excluded from the
analysis. The overall data dropout rate for the ∼102,000
genotypes analyzed was ∼1%.
Data Analysis
Data analysis was done with GENEHUNTER PLUS
(Kong and Cox 1997), a modified version of GENE-
HUNTER (Kruglyak et al. 1996). This software per-
forms multipoint nonparametric linkage analysis by ex-
tracting IBD allele-sharing information among all
affected family members at each location in the genome.
It then derives a nonparametric linkage score (NPL for
GENEHUNTER, Zlr for GENEHUNTER PLUS) on the
basis of the number of affected individuals sharing the
same marker allele IBD. We chose the Sall scoring func-
tion, to allow comparison of observed IBD allele sharing
among all affected family members (not just affected sib
pairs) with that expected under the null hypothesis of
no linkage. LOD scores were generated by the GENE-
HUNTER PLUS software by use of the equation
for each cohort individually and as a2LOD = Z /2 ln 10lr
combined set. Families of various ethnic groups were
similarly extracted from the master linkage file and an-
alyzed separately. Allele frequencies used in the param-
eter files for each analysis were generated from the foun-
der genotypes for that data set (cohort 1, cohort 2,
combined cohorts, individual ethnic groups). Marker-
map positions were obtained from the latest available
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Table 1
Composition of 187 SLE Sib-Pair Families by Cohort
Cohort 1 Cohort 2 Total
No. of sib-pair families 105 82a 187
No. of affected sib pairs 114 93 207
No. of affected relative pairs 127 111 238
No. of affected SLE individuals 220 179 399
No. of unaffected parents and sibs 155 101 256
a Includes one family with affected first cousins only.
Table 2
Clinical and Demographic Features of 399 Patients with
SLE by Cohort
Characteristic Cohort 1 Cohort 2
Age at diagnosis  SD (years) 31  11 34  11
Duration of disease  SD
(years)
12  7 15  9
Sex (F:M) 219:1 175:4
Ethnicity (%):
White 80 78
Hispanic 8 6
Black 5 15
Asian 3 0
Mixed heritage 4 1
Laboratory/clinical features (%):a
ANA positiveb 98 98
Anti-dsDNA positivec 49 42
Arthritis 86 84
Skin involvement 91 87
Pleuritis 54 54
Hematologic 49 40
Renal disease 31 30
CNS lupus 13 15
Pericarditis 18 20
11 Miscarriage 10 6
Medication history (%):a
Corticosteroids 76 85
Antimalarials 65 72
Cytotoxic drugs 28 36
Intravenous steroids 19 21
NOTE.—There were no significant differences in any of these
variables, between cohorts 1 and 2, with use of generalized
estimating equations to adjust for the intrafamilial correlation
(Zeger and Liang 1986).
a Data are percentage of patients with SLE who have the
features at any time during the course of their disease.
b ANA, antinuclear antibodies. All ANA-negative patients
were anti-dsDNA positive and otherwise fulfilled criteria for
SLE.
c dsDNA, double-stranded DNA; CNS, central nervous
system.
sex-averaged maps compiled by J. Weber (Center for
Medical Genetics, Marshfield Medical Research Foun-
dation).
Results
Demographic and Clinical Features of MN Cohort 2
Minnesota SLE cohort 2 consists of 82 families (75
families with 2 SLE sibs, 6 families with 3 SLE sibs, and
1 family with 2 affected first cousins; table 1). Within
the cohort there were 93 affected-sib pairs and 111 total
affected-relative pairs. There were some differences in
the composition of the cohort 2 and cohort 1 families.
In addition to being a smaller collection, cohort 2 had
fewer parental or unaffected sib samples available than
did cohort 1. Whereas only 1 of the 105 families in
cohort 1 was an isolated sib pair (no parents or unaf-
fected sibs), there were 14 such families in the cohort 2
sample of 82 families. There were also fewer total avail-
able unaffected sibs in cohort 2. The ratio of the number
of unaffected parents or sibs divided by the number of
families was 1.23 for cohort 2 (101/82), compared with
1.47 for cohort 1 (155/105). The number of half-sib
families was comparable between the two groups (four
in cohort 2, five in cohort 1).
The clinical and demographic features of cohort 2 are
presented in table 2 and compared with those of cohort
1. Cohort 2 patients with SLE were slightly older at the
time of diagnosis ( vs. years) and had34 11 31 11
disease for a modestly longer period of time ( vs.15 9
years), compared with cohort 1. Both cohorts12 7
are composed of ∼80% white pedigrees. Of the non-
white families, there was a higher percentage of black
pedigrees in cohort 2. The only differences in clinical
features between the cohorts were a slightly lower in-
cidence of hematologic manifestations of SLE (leuko-
penia, autoimmune hemolytic anemia, lymphopenia,
and thrombocytopenia) and a higher percentage of pa-
tients treated with corticosteroids, anti-malarial, and cy-
totoxic medications in cohort 2, compared with cohort
1 (table 2). None of these differences reached statistical
significance ( ).P ! .05
Genome Screen of MN Cohort 2
The cohort 2 pedigrees were genotyped with 366 di-
nucleotide repeat microsatellite markers (ABI linkage
panel, version 2.0), at an average intermarker distance
of 8.9 cM across the 22 autosomes. The data were com-
piled and multipoint nonparametric analysis was done
by use of GENEHUNTER PLUS (Kong and Cox 1997).
A nominal LOD score threshold of 1.0 was chosen.
Twenty-nine positive markers were identified that fell
into 12 discrete chromosomal regions (table 3 and fig.
1). Markers in three of the intervals met criteria for
suggestive linkage (LOD score 12.2), as defined by
Lander and Kruglyak (1995): 7p22 (D7S517, LOD score
2.87), 7q21 (D7S669, LOD score 2.40), and 10p13
(D10S548, LOD score 2.24). The remaining nine inter-
vals contained markers with LOD scores in the range
550 Am. J. Hum. Genet. 66:547–556, 2000
Table 3
Minnesota SLE Cohort 2 Genome Mapping Results
Intervala and
Cohort 2
LOD Scoreb
Positive
Markers
Map
Positionc
(cM)
Information
Contentd
7p22:
2.37 D7S531 .10 .76
2.87 D7S517 2.16 .77
2.07 D7S513 10.40 .75
1.46 D7S507 23.46 .76
7q21:
1.51 D7S502 75.72 .67
2.40 D7S669 88.35 .72
1.90 D7S630 93.16 .75
1.05 D7S657 99.58 .73
10p13:
1.74 D10S1653 39.65 .64
2.24 D10S548 46.24 .62
2.04 D10S197 50.04 .69
1.55 D10S208 56.45 .70
7q36:
1.50 D7S636 157.05 .82
2.15 D7S798 165.95 .77
1.41 D7S2465 174.96 .67
2p23:
1.14 D2S162 15.20 .74
1.46 D2S168 24.19 .75
1.67 D2S305 34.74 .72
1.47 D2S165 39.83 .75
6p22.3-p21.3:
1.06 D6S422 28.43 .74
1.48 D6S276 35.47 .67
2q35:
1.25 D2S325 201.06 .74
1.45 D2S126 212.44 .72
16p13:
1.21 D16S404 7.15 .70
18p11.23:
1.03 D18S63 10.59 .71
1.19 D18S452 16.92 .77
1p36:
1.06 D1S468 .00 .60
8q23:
1.05 D8S1784 114.81 .59
4q32:
1.02 D4S413 162.84 .68
a Chromosome locations were determined on the basis
of data from the Genome Database.
b (Kong and Cox 1997).2LOD = Z /2 ln10lr
c Map positions were from the Center for Medical
Genetics, Marshfield Medical Research Foundation
database.
d Information content for the marker designated in
each interval (Kruglyak et al. 1996). The average infor-
mation content for all the markers in cohort 2 was .69.
1.02–2.15 (table 3). None of the markers in the cohort
2 sample met Lander criteria for significant linkage
(LOD score 13.6).
Combined Analyses of Marker Data from MN Cohorts
1 and 2
We next combined the marker data from cohorts 2
and 1 to determine the overall level of support for link-
age in the best intervals identified in the present cohort
2 study and in the previous cohort 1 study (Gaffney et
al. 1998). The markers for chromosomes 14–22 (102 in
total) were identical for the two cohorts (ABI linkage
panel v2.0). Because chromosomes 1–13 in cohort 1
were genotyped with an earlier version of the ABI link-
age panel (v1.0), only 69% of the chromosome 1–13
markers were the same between the two cohorts (181/
264). Allele frequencies for the parameter files were cal-
culated by combining the parental genotype data from
all families. The combined data set represents ∼230,000
genotypes from 187 SLE families, for a total of 207
affected sib pairs and 238 affected relative pairs (table
1).
The results of the combined multipoint analysis are
shown in figure 1 and summarized in table 4. Evidence
for linkage at 6p11-p21 and 16q13, the two intervals
with the highest LOD scores in the original cohort 1
study, remained strong in the combined analyses. In the
cohort 2 screen, the best marker in the 6p11-p21 interval
was D6S276 (LOD score 1.48). This marker lies ∼16
cM telomeric of D6S426, the peak marker in the region
from the cohort 1 screen (LOD score 4.16). In the com-
bined analysis, the evidence for linkage at D6S426,
which lies just centromeric of the HLA region on 6p,
showed only a slight increase compared with the results
in cohort 1 alone, with an overall LOD score of 4.19.
The evidence for linkage at 16q13 strengthened at
marker D16S415 when both cohorts were considered,
with a combined LOD score of 3.85, compared with a
LOD score of 3.47 from cohort 1 families alone. Both
the 6p11-p21 and 16q13 intervals exceed the threshold
LOD score 13.6 suggested by Lander and Kruglyak
(1995) for significant linkage in the combined sample.
Three of the weaker intervals identified in the cohort
1 screen (LOD scores in the range 1.0–2.0) showed an
increase in LOD score 10.5 in the combined analysis
compared with the cohort 1 alone results: 2p15
(D2S337, LOD score 2.06), 1q42 (D1S235, LOD score
1.92), and 11p15 (D11S922, LOD score 1.60). Of the
two chromosome 20 intervals previously identified in
the cohort 1 screen, evidence for linkage in the combined
analysis of all families dropped at 20p12 (to LOD score
1.77 at marker D20S186), and rose slightly at 20q12
(to LOD score 1.64 at marker D20S119). Cohort 2
showed essentially no evidence for linkage at 14q21-23,
one of the better intervals identified in cohort 1, and in
the combined sample, only a single marker (D14S65,
LOD score 1.20) on chromosome 14 demonstrated a
LOD score 11.0.
Of the four strongest LOD scores obtained in the co-
hort 2 analysis alone (7p22, 7q21, 10p13, and 7q36),
Figure 1 Nonparametric multipoint linkage analysis in 187 sib-pair families. Shown are the LOD-score values for 82 cohort 2 families
(dotted line), 105 cohort 1 families (dashed line), and the combined cohorts (187 families; solid line) across the 22 autosomes. The data were
generated by use of GENEHUNTER PLUS (Kong and Cox 1997) and represent 366 polymorphic markers at an average intermarker interval
of 8.9 cM.
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Table 4
Combined Mapping Results for Minnesota SLE Cohorts 1 and 2
INTERVAL
LOD SCOREa,b
POSITIVE
MARKER
MAP
POSITIONc
(cM)
INFORMATION
CONTENTCohort 1 Cohort 2 Combined
6p11-p21 .96 .74 1.68 D6S289 28.53 .78
.50 .93 1.35 D6S422 34.26 .80
.65 1.48 1.93 D6S276 43.01 .73
) .65 2.38 D6S1610 50.53 .60
4.16 ) 4.19 D6S426 59.04 .60
3.34 .43 3.10 D6S257 78.52 .76
) .67 1.94 D6S460 95.77 .54
.71 .65 1.34 D6S462 101.68 .54
16q13 .74 .57 1.21 D16S3068 36.59 .77
2.99 .44 2.86 D16S3136 51.75 .71
3.47 .72 3.85 D16S415 60.45 .69
1.31 .82 2.14 D16S503 73.19 .74
2p15 1.44 .65 2.06 D2S337 73.09 .82
7q36 .47 1.50 1.69 D7S636 157.05 .82
) 2.04 2.06 D7S798 162.37 .61
1q42 ) .65 1.56 D1S2800 247.90 .75
.68 ) 1.79 D1S446 249.41 .72
1.38 ) 1.92 D1S235 252.75 .68
) .62 1.06 D1S2785 264.93 .46
18p11 .85 1.08 1.78 D18S59 .10 .74
.47 1.19 1.63 D18S452 23.69 .80
20p12 .93 .25 1.33 D20S115 22.78 .70
2.03 .21 1.77 D20S186 30.86 .76
1.97 .02 1.11 D20S112 36.42 .78
20q12 1.59 .33 1.64 D20S119 58.94 .80
11p15 .94 ) 1.60 D11S922 .10 .73
) .64 1.60 D11S4046 1.00 .72
4q32-q33 1.30 .59 1.33 D4S424 145.19 .72
.59 1.02 1.50 D4S1597 162.39 .66
2p24 .55 .99 1.39 D2S162 10.66 .79
1q41 .92 ) 1.33 D1S229 233.51 .73
4p15 .23 .94 1.31 D4S403 16.38 .67
7p22 .26 1.46 1.30 D7S507 24.65 .80
.16 1.20 1.07 D7S493 28.22 .84
14q32 .64 .56 1.20 D14S65 110.84 .71
2q34 .33 1.16 1.16 D2S325 195.29 .79
2q21-q33 1.03 ) 1.14 D2S151 144.44 .59
13q31 .16 .91 1.02 D13S170 54.65 .82
a An ellipsis ()) indicates that the marker was not run in that cohort.
b Data are as described in table 3.
c Position of the highest LOD score for the combined data set, as calculated by GENE-
HUNTER PLUS. The nearest marker to each designated map position is shown.
only 7q36 (D7S798, LOD score 2.06) and 7p22
(D7S507, LOD score 1.30) showed LOD scores 11.0 in
the combined pedigree collection.
Partitioning of the Sample by Ethnicity
Previous genetic epidemiology studies in SLE (re-
viewed in Hochberg 1997a), as well as the recent map-
ping studies (Gaffney et al. 1998; Moser et al. 1998;
Shai et al. 1999; Tsao et al. 1999), indicate that the
genetic susceptibility underlying SLE may differ between
racial groups. Thus, we partitioned the data sets by eth-
nicity. We first examined the group of European-white
pedigrees (65 families) within cohort 2, and compared
the results with the entire 82-family sample (table 5,
top). Although there were minor changes in LOD scores
in all identified intervals, six regions demonstrated a
change in LOD score 10.5 LOD units. Notably, the LOD
score in the 7q21 region, one of the strongest intervals
identified in the cohort 2 screen, dropped to a LOD score
of 1.45 from 2.40.
Next, we partitioned the combined data set (cohorts
1 and 2) and analyzed the evidence for linkage in the
white pedigrees (149 families) and compared these re-
sults with those of the entire sample (table 5, bottom).
Once again, the partitioned data showed minor changes
in LOD scores across the genome. Six intervals showed
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Table 5
Mapping Results in White Pedigrees Compared with Entire Family
Collectiona
LOD SCORE IN COHORT 2
INTERVAL
POSITION
(cM)
All Familiesb
(N = 82)
White Familiesb
(N = 65) Difference
7q21 88.35 2.40 1.45 .95
2q35 212.44 1.45 .56 .88
1p36 .10 1.06 .51 .55
4p15 16.65 .89 1.52 .62
3q24 152.55 .85 1.39 .54
12q24 135.54 .58 1.09 .52
LOD SCORE IN COHORTS 1 AND 2
All Families
(N = 187)
White Families
(N = 149) Difference
6p11-p21 66.83 4.19 2.87 1.32
16q13 60.45 3.85 3.22 .63
1q42 252.75 1.92 1.30 .63
14q32 110.84 1.20 .44 .77
2q21-q33 144.44 1.14 .59 .55
4p16 11.61 1.10 1.63 .53
7p22 6.28 1.04 1.84 .80
13q31 54.65 1.02 .41 .61
3q24 149.59 .81 1.90 1.09
16p13 21.71 .71 1.50 .79
11p15 10.81 .68 1.75 1.07
a Only those regions with a difference 10.5 LOD units (white vs.
all pedigrees) are shown.
b N = number of families for each analysis.
a LOD score drop 10.5 units when only the white fam-
ilies were considered: 6p11-21 (LOD score 2.87, 1.32
LOD units), 16p13 (LOD score 3.22,0.63 LODunits),
1q42 (LOD score 1.30,0.63 LOD units), 14q32 (LOD
score 0.44, 0.77 LOD units), 2q21-33 (LOD score
0.59, 0.55 LOD units), and 13q31 (LOD score .41,
0.61 LOD units). Our interpretation of these LOD
score drops is that pedigrees from all ethnic backgrounds
contribute to the evidence for linkage in these regions.
Conversely, LOD score increases were observed at 4p16,
7p22, 3q24, 16p13, and 11p15, suggesting the possi-
bility of genetic effects enriched within the white sample.
Finally, we also performed a separate genomewide
multipoint analysis for the 17 available black families
and for the 13 Hispanic families. Despite the small num-
ber of families, D2S325 at 2q34 exhibited a LOD score
of 1.1 in the black subgroup, whereas the Hispanic col-
lection demonstrated LOD scores of 1.45 at 13q32
(marker D13S159), 1.34 at 1q42 (marker D1S235), and
1.18 at 19q12 (marker D19S414).
Discussion
In this report, we present the results of a genomewide
marker screen in Minnesota cohort 2, comprising 82
new SLE sib-pair families. When the data from cohort
2 were analyzed separately, the chromosomal regions
with the strongest evidence for linkage were 10p13 and
three distinct intervals on chromosome 7. Eight addi-
tional regions showed LOD scores 11.00. In the com-
bined data set of both cohorts 1 and 2, the cohort 2
families provided additional evidence for linkage in four
of the intervals identified in the previous cohort 1 screen:
16q13, 2p15, 1q42, and 11p15. LOD score increases in
these regions were in the range 0.38–0.66 in the com-
bined data set (187 families), compared with cohort 1
alone (105 families). In the combined data set, evidence
for linkage at 6p11-p21, near HLA, did not change sig-
nificantly and remained strong, whereas scores at 14q21-
23, one of the better intervals identified in cohort 1,
dropped sharply.
Not surprisingly, the mapping results between the two
independent MN cohorts were not entirely analogous.
Although many factors may contribute to the differences
observed, an important issue is the family composition
of the second cohort. Cohort 2 contained a smaller num-
ber of families than did cohort 1 (82 and 105, respec-
tively), and 14 of the 82 cohort 2 families were isolated
sib pairs (neither parents nor unaffected sibs were avail-
able), whereas there was only one such family in cohort
1. There were also fewer parents and unaffected siblings
available for the second cohort. Thus, cohort 2, overall,
has less power to detect linkage than does the cohort 1
collection.
Another consideration is that the markers used for the
two screens were not identical. Although the samemark-
ers were used for chromosomes 14–22 in both screens,
there was only 69% overlap of the markers for chro-
mosomes 1–13 because of differences in the available
screening marker sets. Because evidence for linkage can
extinguish rapidly as one moves away from a region of
interest (Kruglyak 1999), we may have missed evidence
for linkage in either cohort on the basis of the markers
used for the analysis and the relatively large distances
between markers (∼9 cM).
Another potential explanation for differences between
the two screens is that there is almost certainly significant
genetic heterogeneity in human SLE, similar to that sus-
pected in many complex genetic disorders. At least some
of the heterogeneity can be attributed to differences be-
tween ethnic groups (see table 5 and Moser et al. 1998;
Shai et al. 1999). Finally, it is possible that random var-
iation may account for some of the differences we have
found. Overall, the data presented underscore the pre-
sumed complexity of the genetics in SLE.
Perhaps the strongest supportive evidence for a gen-
uine susceptibility locus in any complex disease, short
of actually isolating the gene, is the independent repli-
cation of linkage results in independent family collec-
tions. This was one of the aims of the present study.
However, in addition to the work performed by our
group, there are now available two additional published
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Table 6
Proposed Human SLE Susceptibility Loci Identified in Two or More Mapping Studies
Locus
Gaffney
Cohort 1
Gaffney
Cohort 2 Moser Shai Tsaoa
Maximum
Marker Intervalb
(cM)
1p36 D1S234 D1S468 D1S468 24
1q23 FcgRIIA D1S484 1
1q41-44 D1S235 D1S3462 D1S2785 D1S229 16
2q32-35 D2S126 D2S1391 17
3q11 D3S1271 D3S2406 10
4p15 D4S403c D4S403 0
4q28-31 D4S424 D4S413 D4S2431 16
6p11-22 D6S426c D6S276 14
14q11-23 D14S276 D14S258 21
16q12-13 D16S415 D16S3136 2
20p12-13 D20S186 D20S115 7
20q11-13 D20S119 D20S481 D20S195 4
a Targeted study of chromosome 1q only.
b Between the two most widely spaced markers showing evidence for linkage within each
locus (25 cM was the maximum allowable intermarker distance). Marker locations were de-
termined on the basis of data from maps available at the Genetic Location Database, University
of Southhampton.
c On the basis of LOD score from combined Minnesota cohort 1 and 2 analyses.
genome screens in human SLE (Moser et al. 1998; Shai
et al. 1999), as well as a targeted marker analysis of
distal chromosome 1q (Tsao et al. 1997, 1999), to com-
pare with our results.
Moser et al. at Oklahoma Medical Research Foun-
dation studied 94 multiplex SLE families by using pri-
marily parametric analytical methods and a nominal
threshold of LOD 11.5 (Moser et al. 1998). Potential
susceptibility loci were identified on 1q23, 1q31, 13q32,
and 20q13 in the combined pedigree collection. When
the data were stratified by race, additional loci at 1q41
and 11q14-23 were identified in black families, which
comprised about a third of the sample. In European-
white families, the strongest evidence for linkage was at
14q11, 4p15, 11q25, 2q32, 19q13, 6q26-27, and
12p12-11. Shai et al. at the University of Southern Cal-
ifornia (USC) performed a genomewide screen in 80mul-
tiplex SLE families (Shai et al. 1999). The two strongest
intervals identified in this collection by GENEHUNTER
multipoint analyses were 1q44 and 18q21. Significant
scores were also obtained at 1p36, 1p21, 1q24, 6p22,
14q23, 16q13, 20p13, and 20q11. Finally, in a targeted
study of distal chromosome 1q, Tsao et al. reported ev-
idence for an SLE susceptibility gene in the region of
1q42 (Tsao et al. 1997, 1999).
Although there are significant differences between the
reported mapping studies in SLE in terms of family struc-
tures, ethnicity, and analytical techniques used, there is
an encouraging level of agreement in the mapping re-
sults. Table 6 provides a summary of potential SLE sus-
ceptibility loci identified in two or more independent
screens. These 12 intervals were defined as follows: (1)
LOD score 11.0 or NPL score 11.5 and (2) intermarker
distance 25 cM. Particularly striking were the results
from the Minnesota cohort 1 and USC screens. Seven
of the 10 regions identified by Shai et al. (1999) were
among the 13 top intervals identified in Minnesota co-
hort 1, and 5 of the best 10 intervals from the combined
Minnesota analyses were supported by the USC study.
These similarities may reflect the fact that both groups
studied predominantly sib-pair families using similar
marker panels and that both data sets were analyzed
with allele-sharing methods.
Remarkably, the interval at 1q42 (around marker
D1S229) shows evidence for linkage in all of the SLE
mapping studies reported to date. This interval was orig-
inally identified by Tsao et al. (1997), and poly-ADP
ribosyl transferase (PARP) was recently suggested as the
relevant gene in the region on the basis of strong TDT
scores with a polymorphic marker in the 5′ region of the
gene (Tsao et al. 1999). Although recent results in our
family collection do not support PARP as being the spe-
cific gene of interest (unpublished data), this region of
the genome will continue to be a focus for future
investigations.
Significant evidence for linkage in our combined co-
hort analysis was also found over a broad interval span-
ning 6p11-p21, with the best markers (D6S426 and
D6S257) mapping just centromeric to the HLA region
(located at 6p21.3). Evidence for linkage in this region
was also obtained in the USC study, with marker
D6S276 (14 cM telomeric to D6S426) giving a LOD
score of 1.60. This same marker achieved a LOD score
of 1.48 in our cohort 2 screen. The HLA region has long
been implicated as a susceptibility locus in SLE (Arnett
1997), as well as in many other autoimmune diseases,
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including type 1 diabetes, psoriasis, multiple sclerosis,
and rheumatoid arthritis (Nepom and Erlich 1991). It
remains to be determined whether the linkage identified
in this interval represents a polymorphic HLA locus or
a linked gene(s) within the HLA region.
The 16q13 region identified in the Minnesota and
USC cohorts is of interest because of its identification in
other autoimmune diseases, including psoriasis (Nair et
al. 1997), Crohn’s disease (Hugot et al. 1996; Curran
et al. 1998; Mirza et al. 1998; Hampe et al. 1999), Blau
syndrome (Tromp et al. 1996), type 1 diabetes (Davies
et al. 1994), and asthma (Daniels et al. 1996). In ad-
dition, the 20p12 region, identified in theMinnesota and
USC screens, maps close to a recently identified putative
susceptibility locus for psoriasis (Nair et al. 1997; Trem-
bath et al. 1997), whereas the 20q12 locus, identified in
all three SLE genome screens, maps to a potential sus-
ceptibility region for Grave’s disease (Tomer et al. 1998).
The clustering of different autoimmune diseases in fam-
ilies (Bias et al. 1986) and the apparent sharing of sus-
ceptibility loci between various autoimmune disorders
(Becker et al. 1998) suggests that genes within the iden-
tified SLE intervals may be important for predisposition
to autoimmunity in general.
The first wave of genome screens in human SLE, in-
cluding the data reported here, support the hypothesis
that multiple genes contribute to disease susceptibility.
Clearly, there is no single locus operating in all families
multiplex for SLE, and the degree of ethnic and genetic
heterogeneity appears be quite significant. In this respect,
the genetics of SLE resembles that of many other com-
plex genetic diseases. Fine mapping and candidate gene
sequencing efforts in these intervals are under way, with
a goal of eventually identifying major genes predisposing
to human SLE.
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